{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:49:38Z","timestamp":1787849378051,"version":"build-2784847793"},"reference-count":132,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parathyroid hormone is the main hormonal regulator of bone remodeling; thus, chronic hypoparathyroidism (HypoPT) leads to low bone turnover that might compromise bone strength, despite the normal or even high bone mineral density. Recent studies suggest that fracture risk might be increased in patients with HypoPT. Given that all available treatments for osteoporosis affect bone remodeling, management of bone fragility of any etiology in patients with HypoPT is challenging and lacks clinical evidence in terms of fracture risk reduction. In the present article, we describe the changes in bone remodeling and bone strength in patients with chronic HypoPT managed by conventional therapy and under PTH replacement. In addition, based on pathophysiology and the limited existing evidence, we discuss which osteoporosis medication could be used in patients with HypoPT and concurrent increased bone fragility. In HypoPT patients under conventional treatment with calcium and active vitamin D, administration of potent antiresorptives (bisphosphonates, denosumab) should be done under close monitoring, given their antiremodeling action that might result in hypocalcemia; the effect on bone material properties is not known. Teriparatide is probably the best available option, at least in the short term. In contrast, patients with HypoPT on long-term PTH replacement therapy who experience fragility fractures should probably be treated with antiresorptives, although the optimal therapeutic regimen, in terms of safety and efficacy, is yet unknown.<\/jats:p>","DOI":"10.1210\/clinem\/dgag160","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:47:35Z","timestamp":1775821655000},"page":"e2030-e2042","source":"Crossref","is-referenced-by-count":2,"title":["Approach to the patient: management of bone fragility in patients with chronic hypoparathyroidism"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-324X","authenticated-orcid":false,"given":"Symeon","family":"Tournis","sequence":"first","affiliation":[{"name":"Laboratory for Research of the Musculoskeletal System \u201cTh. Garofalidis\u201d, Medical School, National and Kapodistrian University of Athens, KAT Hospital , Athens 14561 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Kassi","sequence":"additional","affiliation":[{"name":"Centre of Expertise in Rare Endocrine Diseases, C.E.R.E.D \u2013Disorders of Calcium and Phosphate Metabolism, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, LAIKO General Hospital of Athens, National and Kapodistrian University of Athens , Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P","family":"Yavropoulou","sequence":"additional","affiliation":[{"name":"Centre of Expertise in Rare Endocrine Diseases, C.E.R.E.D \u2013Disorders of Calcium and Phosphate Metabolism, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, LAIKO General Hospital of Athens, National and Kapodistrian University of Athens , Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Adamidou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Hippokratio General Hospital , Thessaloniki 54642 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine, \u201cPapageorgiou\u201d General Hospital, Aristotle University of Thessaloniki , Thessaloniki 56403 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Air Force General Hospital , Athens 11525 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D","family":"Anastasilakis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 424 General Military Hospital , Thessaloniki 56429 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"2026071419574126600_dgag160-B1","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026071419574126600_dgag160-B2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3803\/EnM.2024.1916","article-title":"Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone","volume":"39","author":"Rejnmark","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2026071419574126600_dgag160-B3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-025-00905-6","article-title":"PTH substitution therapy for chronic hypoparathyroidism: PTH 1-84 and palopegteriparatide","volume":"23","author":"Palermo","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"21","key":"2026071419574126600_dgag160-B4","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2026071419574126600_dgag160-B5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1210\/endrev\/bnaf010","article-title":"Bone in parathyroid diseases revisited: evidence from epidemiological, surgical and new drug outcomes","volume":"46","author":"Roumpou","year":"2025","journal-title":"Endocr Rev"},{"issue":"12","key":"2026071419574126600_dgag160-B6","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419574126600_dgag160-B7","first-page":"1617","article-title":"Bone mineral density in patients with chronic hypoparathyroidism","volume":"76","author":"Abugassa","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026071419574126600_dgag160-B8","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026071419574126600_dgag160-B9","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2002-021388","article-title":"Increased bone mineral density in patients with chronic hypoparathyroidism","volume":"88","author":"Chan","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419574126600_dgag160-B10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12020-023-03495-4","article-title":"Chronic hypoparathyroidism is associated with increased cortical bone density evaluated using high-resolution peripheral quantitative computed tomography","volume":"82","author":"Santa Rosa","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"2026071419574126600_dgag160-B11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40618-023-02177-2","article-title":"Features of patients and fracture risk in hypoparathyroidism; a single center study","volume":"47","author":"Slutzky-Shraga","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026071419574126600_dgag160-B12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00198-025-07410-7","article-title":"Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian national hypoparathyroidism registry (CNHR)","volume":"36","author":"Khan","year":"2025","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026071419574126600_dgag160-B13","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026071419574126600_dgag160-B14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/clinem\/dgab076","article-title":"Vertebral fracture assessment in postmenopausal women with postsurgical hypoparathyroidism","volume":"106","author":"Cipriani","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071419574126600_dgag160-B15","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40618-022-01818-2","article-title":"Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism","volume":"45","author":"Saha","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2026071419574126600_dgag160-B16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jbmr\/zjaf061","article-title":"Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a nationwide cohort study in Sweden","volume":"40","author":"Bj\u00f6rnsdottir","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026071419574126600_dgag160-B17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00198-021-05966-8","article-title":"Fracture risk in hypoparathyroidism: a systematic review and meta-analysis","volume":"32","author":"Pal","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419574126600_dgag160-B18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jbmr.2609","article-title":"Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism","volume":"31","author":"Cusano","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419574126600_dgag160-B19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jbmr.2588","article-title":"PTH(1-84) administration in hypoparathyroidism transiently reduces bone matrix mineralization","volume":"31","author":"Misof","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026071419574126600_dgag160-B20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-019-05177-2","article-title":"PTH and bone material strength in hypoparathyroidism as measured by impact microindentation","volume":"31","author":"Starr","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419574126600_dgag160-B21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jbmr.4816","article-title":"Increased bone material strength index is positively associated with the risk of incident osteoporotic fractures in older Swedish women","volume":"38","author":"Jaiswal","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026071419574126600_dgag160-B22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00198-015-3419-0","article-title":"Bone material strength is associated with areal BMD but not with prevalent fractures in older women","volume":"27","author":"Rud\u00e4ng","year":"2016","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026071419574126600_dgag160-B23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jbmr.4780","article-title":"The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1-84)","volume":"38","author":"Agarwal","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026071419574126600_dgag160-B24","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jbmr.4005","article-title":"Changes in skeletal microstructure through four continuous years of rhPTH(1-84) therapy in hypoparathyroidism","volume":"35","author":"Cusano","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026071419574126600_dgag160-B25","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026071419574126600_dgag160-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156335","article-title":"Best practice recommendations for the diagnosis and management of hypoparathyroidism","volume":"171","author":"Khan","year":"2025","journal-title":"Metabolism"},{"issue":"3","key":"2026071419574126600_dgag160-B27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1210\/endrev\/bnac032","article-title":"Molecular mechanisms of PTH\/PTHrP class B GPCR signaling and pharmacological implications","volume":"44","author":"Vilardaga","year":"2023","journal-title":"Endocr Rev"},{"issue":"4","key":"2026071419574126600_dgag160-B28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/endrev\/bnab005","article-title":"Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R","volume":"42","author":"Martin","year":"2021","journal-title":"Endocr Rev"},{"key":"2026071419574126600_dgag160-B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114669","article-title":"Parathyroid hormone and its related peptides in bone metabolism","volume":"192","author":"Chen","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"2026071419574126600_dgag160-B30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41574-024-01014-7","article-title":"PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus","volume":"20","author":"Marino","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2026071419574126600_dgag160-B31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/8756-3282(95)00443-2","article-title":"Bone histomorphometry in hypoparathyroid patients treated with vitamin D","volume":"18","author":"Langdahl","year":"1996","journal-title":"Bone"},{"issue":"1","key":"2026071419574126600_dgag160-B32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bone.2009.09.020","article-title":"Three dimensional cancellous bone structure in hypoparathyroidism","volume":"46","author":"Rubin","year":"2010","journal-title":"Bone"},{"issue":"4","key":"2026071419574126600_dgag160-B33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2265.2006.02479.x","article-title":"Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism","volume":"64","author":"Laway","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026071419574126600_dgag160-B34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jbmr.3638","article-title":"Bone matrix mineralization in patients with gain-of-function calcium-sensing receptor mutations is distinctly different from that in postsurgical hypoparathyroidism","volume":"34","author":"Ovejero","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2026071419574126600_dgag160-B35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","article-title":"A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor","volume":"335","author":"Pearce","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"2026071419574126600_dgag160-B36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000303188","article-title":"Phenotypic variation in a large family with autosomal dominant hypocalcaemia","volume":"74","author":"S\u00f8rheim","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"2026071419574126600_dgag160-B37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00198-020-05506-w","article-title":"Bone microstructure of adult patients with non-surgical hypoparathyroidism assessed by high-resolution peripheral quantitative computed tomography","volume":"31","author":"Liu","year":"2020","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419574126600_dgag160-B38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12020-016-1101-8","article-title":"Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism","volume":"55","author":"Cipriani","year":"2017","journal-title":"Endocrine"},{"issue":"6","key":"2026071419574126600_dgag160-B39","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jbmr.3078","article-title":"Understanding bone strength is not enough","volume":"32","author":"Hernandez","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2026071419574126600_dgag160-B40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117274","article-title":"Predictors of lumbar spine trabecular bone score in women with postsurgical hypoparathyroidism","volume":"190","author":"Carvalho","year":"2025","journal-title":"Bone"},{"key":"2026071419574126600_dgag160-B41","article-title":"Morphometric vertebral fracture risk in women with postsurgical hypoparathyroidism","volume":"13","author":"d'Alva","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2026071419574126600_dgag160-B42","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jbmr.4871","article-title":"Risk of fractures in thyroid cancer patients with postoperative hypoparathyroidism: a nationwide cohort study in Korea","volume":"38","author":"Ahn","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026071419574126600_dgag160-B43","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1210\/jc.2019-00698","article-title":"Predictors of poor bone microarchitecture assessed by trabecular bone score in postsurgical hypoparathyroidism","volume":"104","author":"Sakane","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574126600_dgag160-B44","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.723532","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"9","author":"Ferr\u00e9","year":"2021","journal-title":"Front Pediatr"},{"key":"2026071419574126600_dgag160-B45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fendo.2020.00109","article-title":"Severe phenotype of APECED (APS1) increases risk for structural bone alterations","volume":"11","author":"Laakso","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026071419574126600_dgag160-B46","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal dominant hypocalcemia type 1: a systematic review","volume":"37","author":"Roszko","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419574126600_dgag160-B47","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419574126600_dgag160-B48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00198-012-2230-4","article-title":"PTH replacement therapy of hypoparathyroidism","volume":"24","author":"Rejnmark","year":"2013","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026071419574126600_dgag160-B49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jbmr\/zjaf118","article-title":"Advances in parathyroid hormone-based medicines","volume":"40","author":"Bonnet","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419574126600_dgag160-B50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41584-025-01287-w","article-title":"Parathyroid hormone receptor agonists in the management of osteoporosis","volume":"21","author":"Fuggle","year":"2025","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"2026071419574126600_dgag160-B51","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-025-07612-z","article-title":"The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review","volume":"36","author":"Thomsen","year":"2025","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419574126600_dgag160-B52","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"4","key":"2026071419574126600_dgag160-B53","first-page":"477","article-title":"Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone","volume":"16","author":"Uzawa","year":"1995","journal-title":"Bone"},{"issue":"12","key":"2026071419574126600_dgag160-B54","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119491","article-title":"Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells","volume":"99","author":"Ishizuya","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"2026071419574126600_dgag160-B55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcb.20438","article-title":"Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray","volume":"95","author":"Onyia","year":"2005","journal-title":"J Cell Biochem"},{"key":"2026071419574126600_dgag160-B56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2018.09.018","article-title":"Advances in the treatment of hypoparathyroidism with PTH 1-34","volume":"120","author":"Winer","year":"2019","journal-title":"Bone"},{"issue":"12","key":"2026071419574126600_dgag160-B57","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/jbmr.4676","article-title":"Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026071419574126600_dgag160-B58","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026071419574126600_dgag160-B59","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574126600_dgag160-B60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"11","key":"2026071419574126600_dgag160-B61","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419574126600_dgag160-B62","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026071419574126600_dgag160-B63","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419574126600_dgag160-B64","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026071419574126600_dgag160-B65","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026071419574126600_dgag160-B66","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419574126600_dgag160-B67","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419574126600_dgag160-B68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026071419574126600_dgag160-B69","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574126600_dgag160-B70","author":"Rubin"},{"issue":"1","key":"2026071419574126600_dgag160-B71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"9","key":"2026071419574126600_dgag160-B72","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","article-title":"An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism","volume":"109","author":"Takacs","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2026071419574126600_dgag160-B73","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"2026071419574126600_dgag160-B74","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00198-022-06435-6","article-title":"Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan","volume":"33","author":"Vandenput","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026071419574126600_dgag160-B75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","article-title":"Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419574126600_dgag160-B76","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00223-021-00930-4","article-title":"Practical considerations for the clinical application of bone turnover markers in osteoporosis","volume":"112","author":"Vasikaran","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026071419574126600_dgag160-B77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-022-06567-9","article-title":"The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis","volume":"34","author":"Kanis","year":"2023","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419574126600_dgag160-B78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419574126600_dgag160-B79","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00198-022-06457-0","article-title":"Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study","volume":"33","author":"B\u00f8nl\u00f8kke","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026071419574126600_dgag160-B80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2026071419574126600_dgag160-B81","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419574126600_dgag160-B82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419574126600_dgag160-B83","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2026071419574126600_dgag160-B84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"issue":"10","key":"2026071419574126600_dgag160-B85","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","article-title":"Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers","volume":"64","author":"Anastasilakis","year":"2015","journal-title":"Metabolism"},{"issue":"8","key":"2026071419574126600_dgag160-B86","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026071419574126600_dgag160-B87","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/healthcare10071332","article-title":"Incidence and risk of anti-resorptive agent-related osteonecrosis of the jaw after tooth extraction: a retrospective study","volume":"10","author":"Shimizu","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"5","key":"2026071419574126600_dgag160-B88","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1172\/JCI45890","article-title":"Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization","volume":"122","author":"Lieben","year":"2012","journal-title":"J Clin Invest"},{"issue":"7","key":"2026071419574126600_dgag160-B89","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026071419574126600_dgag160-B90","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2026071419574126600_dgag160-B91","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026071419574126600_dgag160-B92","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071419574126600_dgag160-B93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00198-023-06926-0","article-title":"Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection","volume":"35","author":"Sp\u00e5ngeus","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026071419574126600_dgag160-B94","article-title":"Analysis of adverse drug reactions of denosumab (prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"2026071419574126600_dgag160-B95","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026071419574126600_dgag160-B96","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","article-title":"Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study","volume":"39","author":"Tanaka","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"18","key":"2026071419574126600_dgag160-B97","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2026071419574126600_dgag160-B98","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00774-021-01231-4","article-title":"Early adverse events after the first administration of zoledronic acid in Japanese patients with osteoporosis","volume":"39","author":"Takada","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2026071419574126600_dgag160-B99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0889-8529(02)00079-8","article-title":"Bisphosphonates","volume":"32","author":"McClung","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"897","key":"2026071419574126600_dgag160-B100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/pmj.76.897.417","article-title":"Hypoparathyroidism unmasked by alendronate","volume":"76","author":"Kashyap","year":"2000","journal-title":"Postgrad Med J"},{"issue":"4_Part_1","key":"2026071419574126600_dgag160-B101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-130-4-199902160-00008","article-title":"Hypocalcemia associated with alendronate","volume":"130","author":"Schussheim","year":"1999","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026071419574126600_dgag160-B102","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2011-0418","article-title":"Seizures associated with zoledronic acid for osteoporosis","volume":"96","author":"Tsourdi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419574126600_dgag160-B103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/87551225211070978","article-title":"Seizures associated with bone density conservation agents","volume":"38","author":"Sturgill","year":"2022","journal-title":"J Pharm Technol"},{"issue":"3","key":"2026071419574126600_dgag160-B104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","article-title":"Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study","volume":"80","author":"Khan","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"2026071419574126600_dgag160-B105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"2026071419574126600_dgag160-B106","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10441","article-title":"Comparable initial engagement of intracellular signaling pathways by parathyroid hormone receptor ligands teriparatide. Abaloparatide, and long-acting PTH","volume":"5","author":"Sato","year":"2021","journal-title":"JBMR Plus"},{"issue":"7","key":"2026071419574126600_dgag160-B107","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026071419574126600_dgag160-B108","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1210\/jc.2011-0566","article-title":"Circulating sclerostin in disorders of parathyroid gland function","volume":"96","author":"Costa","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2026071419574126600_dgag160-B109","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2026071419574126600_dgag160-B110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071419574126600_dgag160-B111","first-page":"281","article-title":"The parathyroid hormone circadian rhythm is truly endogenous\u2013a general clinical research center study","volume":"82","author":"el-Hajj Fuleihan","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026071419574126600_dgag160-B112","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s00198-012-1955-4","article-title":"Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"23","author":"Michalska","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419574126600_dgag160-B113","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s13018-025-06083-6","article-title":"Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial","volume":"20","author":"Wang","year":"2025","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"2026071419574126600_dgag160-B114","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bcp.13455","article-title":"Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism\u2014translating the pharmacology","volume":"84","author":"Tay","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"9886","key":"2026071419574126600_dgag160-B115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"2026071419574126600_dgag160-B116","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026071419574126600_dgag160-B117","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026071419574126600_dgag160-B118","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419574126600_dgag160-B119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone"},{"key":"2026071419574126600_dgag160-B120","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2147\/TCRM.S123172","article-title":"High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis","volume":"12","author":"Ishikawa","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"2026071419574126600_dgag160-B121","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziaf013","article-title":"Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab","volume":"9","author":"Tsuchiya","year":"2025","journal-title":"JBMR Plus"},{"issue":"8","key":"2026071419574126600_dgag160-B122","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419574126600_dgag160-B123","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00774-010-0198-8","article-title":"Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease","volume":"28","author":"Polyzos","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"2026071419574126600_dgag160-B124","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026071419574126600_dgag160-B125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419574126600_dgag160-B126","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jbmr\/zjae055","article-title":"Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment","volume":"39","author":"Eriksen","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419574126600_dgag160-B127","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419574126600_dgag160-B128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419574126600_dgag160-B129","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real-world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"2026071419574126600_dgag160-B130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M21-2512","article-title":"Comparative fracture risk during osteoporosis drug holidays after long-term risedronate versus alendronate therapy: a propensity score-matched cohort study","volume":"175","author":"Hayes","year":"2022","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026071419574126600_dgag160-B131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"issue":"1","key":"2026071419574126600_dgag160-B132","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40520-025-03139-9","article-title":"Bone status in patients with chronic hypoparathyroidism: results from the Italian HypoparaNET database","volume":"37","author":"Marini","year":"2025","journal-title":"Aging Clin Exp Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag160\/68033157\/dgag160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/e2030\/68033157\/dgag160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/e2030\/68033157\/dgag160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:58:12Z","timestamp":1784073492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/8\/e2030\/8651660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":132,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,11]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag160","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,11]]}}}